EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ENACTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aditx Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Amro Albanna, Chief Executive Officer of the Company, Corinne Pankovcin, Chief Financial Officer of the Company, and Thomas J. Farley, Controller of the Company, certify, pursuant to 18 U.S.C. § 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| May 12, 2021 | /s/ Amro Albanna |
| Amro Albanna | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
| May 12, 2021 | /s/ Corinne Pankovcin |
| Corinne Pankovcin | |
| Chief Financial Officer | |
| (Principal Financial Officer) | |
| May 12, 2021 | /s/ Thomas J. Farley |
| Thomas J. Farley | |
| Controller | |
| (Principal Accounting Officer) |
